Form 4: Tyra Biosciences Director Acquires Stock Options

Tyra Biosciences Director Stephen Rothenberg acquired stock options for 13,160 shares of common stock.

Summary

• Stephen Rothenberg, a Director at Tyra Biosciences, Inc., was granted stock options on May 28, 2026.
• The options are for 13,160 shares of common stock with an exercise price of $32.68 per share.
• These options vest monthly over a period of 12 months, starting from the grant date.
• Any unvested portion will vest on the date of the next annual stockholder meeting, provided continuous service is maintained.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard compensation event for a director rather than a significant financial or strategic development for the company.

Positives

• Director Stephen Rothenberg has acquired significant stock options, indicating a commitment to the company's future performance.
• The vesting schedule aligns with continuous service, incentivizing long-term engagement.

Risks

• The vesting of remaining unvested options is contingent upon the occurrence of the next annual stockholder meeting, which could introduce a timing uncertainty for full vesting.
• The exercise price of $32.68 per share means the options will only be profitable if the stock price increases above this level.

Future Outlook

The stock options granted have an expiration date of May 27, 2036, and a vesting schedule tied to monthly increments and the company's annual stockholder meeting.

Industry Context

StockSavvy.ai notes that the granting of stock options to directors is a common practice in the biotechnology and pharmaceutical sectors, aligning executive incentives with shareholder value creation.

Stakeholder Impact

• Shareholders: The issuance of options could lead to future dilution if exercised, but also aligns director incentives with stock performance.
• Employees: The compensation structure for directors may indirectly influence overall employee compensation strategies.
• Management: Reinforces the alignment of director compensation with company performance.

Next Steps

• Monthly vesting of 1/12th of the option shares.
• Potential full vesting of remaining unvested options on the date of the next annual stockholder meeting.

Key Dates

Keywords

Tyra Biosciences, TYRA, Form 4, Stock Options, Director Compensation, Beneficial Ownership, SEC Filing